Cargando…

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations

The association of BRCA mutation status with hypersensitivity reactions (HSRs) to carboplatin has gained interest in recent years, particularly in patients with ovarian, fallopian tube, and primary peritoneal cancer. The primary objective of this study is to determine whether the presence of BRCA mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Andrew, Frahm, Corey, Jeter, Joanne M., Abraham, Ivo, Chambers, Setsuko K., Cragun, Janiel M., McBride, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779569/ https://www.ncbi.nlm.nih.gov/pubmed/33457057 http://dx.doi.org/10.6004/jadpro.2019.10.5.2

Ejemplares similares

Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers
por: Ha, Hyeong In, et al.
Publicado: (2020)

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study
por: Gupta, Sudeep, et al.
Publicado: (2021)

Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube
por: Choi, Min Chul, et al.
Publicado: (2018)

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study
por: Lertkhachonsuk, Arb-Aroon, et al.
Publicado: (2020)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

Erratum: Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube
por: Choi, Min Chul, et al.
Publicado: (2018)

Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels
por: Crosbie, Emma J., et al.
Publicado: (2020)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution
por: Bartlett, Thomas E., et al.
Publicado: (2016)

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation
por: Badiner, Nora, et al.
Publicado: (2021)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
por: Sobecki, Janelle N., et al.
Publicado: (2020)

Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy
por: Chen, Hao, et al.
Publicado: (2016)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube
por: Boltežar, Lučka, et al.
Publicado: (2020)

Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis
por: Yucer, Nur, et al.
Publicado: (2021)

Peritoneal Dialysis Catheter−Fallopian Tube Fistula
por: Mandalapu, Rajendra, et al.
Publicado: (2020)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy
por: Lorusso, Domenica, et al.
Publicado: (2013)

Tumorigenesis and peritoneal colonization from fallopian tube epithelium
por: Eddie, Sharon L., et al.
Publicado: (2015)

Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
por: Hur, Young Min, et al.
Publicado: (2021)

Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium
por: Wang, Yiying, et al.
Publicado: (2013)

Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1
por: Ratanaphan, Adisorn, et al.
Publicado: (2014)

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers
por: Mercier, Ann Marie, et al.
Publicado: (2023)

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
por: van der Biessen, Diane A. J., et al.
Publicado: (2018)

Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
por: Kim, Se Ik, et al.
Publicado: (2020)

Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
por: Shakir, Abdur R.
Publicado: (2014)

BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells()()
por: Hollingsworth, Julia, et al.
Publicado: (2018)

Paraganglioma of the Fallopian Tube Presenting as Isolated Fallopian Tube Torsion
por: Takeda, Akihiro, et al.
Publicado: (2022)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study
por: Garrick, Iana, et al.
Publicado: (2022)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Case Report: Stage IIIc primary malignant mixed Müllerian tumor of the fallopian tube: A case of 5-year disease-free survival after cytoreductive surgery combined with peritoneal resection and adjuvant chemotherapy with paclitaxel plus carboplatin
por: Xiao, Xiaoli, et al.
Publicado: (2022)

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment
por: Heijns, Joan B., et al.
Publicado: (2008)

Duplication of the fallopian tube
por: R, Narayanan, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_sntmiqg7k2j5kt99jumck626gf